Author

Yu. V. Gagarina

Observed names: Yu.V. Gagarina, Гагарина Ю. В.

Observed institution: Sechenov University

ORCID: 0000-0002-4459-3034

Observed ORCID: 0000-0002-4459-3034

OpenAlex ID: A5108311069

Сost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction

2023 · M. V. Zhuravleva, S. N. Tereshchenko, et al. · Russian Journal of Cardiology · 5

PDF

Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024

2021 · M. V. Zhuravleva, S. K. Zyryanov, et al. · Russian Journal of Cardiology · 4

PDF

Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy

2023 · M. V. Zhuravleva, V. P. Chulanov, et al. · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · 3

PDF

Expected effect of palivizumab on the reduction of infant mortality and hospitalizations rates due to respiratory syncytial virus infection

2022 · M.V. Zhuravleva, Yu.V. Gagarina, et al. · Voprosy praktičeskoj pediatrii · 3

Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure

2021 · M. V. Zhuravleva, S. N. Tereshchenko, et al. · Russian Journal of Cardiology · 3

PDF

Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases

2020 · M. V. Zhuravleva, S. N. Tereshchenko, et al. · Russian Journal of Cardiology · 3

PDF

Contribution of ticagrelor therapy in patients with acute coronary syndrome and patients with myocardial infarction to the achievement of State Program "Health Development" target in Russia as a whole and Russian regions in 2023-2025

2023 · M. V. Zhuravleva, S. K. Zyryanov, et al. · Russian Journal of Cardiology · 2

PDF

Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction

2024 · M. V. Zhuravleva, S. V. Nedogoda, et al. · Russian Journal of Cardiology · 1

PDF

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings

2022 · M. V. Zhuravleva, S. N. Avdeev, et al. · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · 1

PDF

Comparative pharmacoeconomic analysis of romiplostim and eltrombopag for the chronic idiopathic thrombocytopenic purpura in Russian Federation

2022 · M.V. Zhuravleva, S.S. Bessemeltsev, et al. · Medical Technologies Assessment and Choice · 1

Clinical and economic impact of screening for Fabry disease in children from high risk groups

2021 · M.V. Zhuravleva, T.V. Khimich, et al. · Clinical pharmacology and therapy · 1

PDF

Economic analysis of enzyme replacement therapy for Fabry disease

2019 · M.V. Zhuravleva, T.V. Khimich, et al. · Clinical pharmacology and therapy · 1

PDF

Comparative cost-effectiveness analysis of therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and high cardiovascular risk or a history of atherosclerotic cardiovascular diseases in the Russian healthcare system

2026 · M. V. Zhuravleva, Yu. V. Gagarina, et al. · Russian Journal of Cardiology

PDF

Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program "Health Development" in patients with heart failure

2023 · M. V. Zhuravleva, S. N. Tereshchenko, et al. · Russian Journal of Cardiology

PDF

Effect of ticagrelor in patients with acute coronary syndrome on the achievement of the targets of federal project on the prevention of cardiovascular diseases: 3-year perspective estimates

2020 · M. V. Zhuravleva, F. N. Paleev, et al. · Russian Journal of Cardiology

PDF

Оценка эффективности затрат на предотвращение сердечно-сосудистой смерти и достижение целевого показателя "снижение смертности населения от болезней системы кровообращения" государственной программы "Развитие здравоохранения" при применении препаратов класса ингибиторов натрий-глюкозного котранспортера 2 типа в составе лекарственной терапии хронической болезни почек у пациентов с резистентной артериальной гипертензией

· Журавлева М. В., Гагарина Ю. В., et al. · CyberLeninK (CyberLeninka)

Сравнительный клинико-экономический анализ применения ингибиторов натрий-глюкозного котранспортера 2 типа и агонистов рецепторов глюкагоноподобного пептида‑1 у пациентов с сахарным диабетом 2 типа и высоким сердечно-сосудистым риском или наличием атеросклеротических сердечно-сосудистых заболеваний в анамнезе в условиях российской системы здравоохранения

· Журавлева М. В., Гагарина Ю. В., et al. · CyberLeninK (CyberLeninka)

Works count: 20

Citation count: 28

H-index: 3

I10-index: